Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2261-2270

  Shinsato, Yoshinari ^a   Furukawa, Tatsuhiko ^a   Yunoue, Shunji ^a   Yonezawa, Hajime ^a   Minami, Kentarou ^a   Nishizawa, Yukihiko ^a   Ikeda, Ryuji ^a   Kawahara, Kohichi ^a   Yamamoto, Masatatsu ^a   Hirano, Hirofumi ^a   Tokimura, Hiroshi ^a   Arita, Kazunori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Glioblastoma; MLH1; MutL alpha; PMS2; Recurrence; Resistance; Temozolomide

Indexed keywords

CASPASE 3; MESSENGER RNA; MESYLIC ACID METHYL ESTER; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLNITRONITROSOGUANIDINE; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; NIMUSTINE; PROTEIN MLH1; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CELL ISOLATION; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DACARBAZINE; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84891957320     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1302     Document Type: Article

References (27)

1. Cohen MH, Johnson JR and Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(19 Pt 1):6767-6771.
2. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO and Leyvraz S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20(5):1375-1382.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10):987-996.
4. Schofield MJ and Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annual review of microbiology. 2003; 57:579-608.
5. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ and Louis DN. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(7):2038-2045.
6. Stark AM, Doukas A, Hugo HH and Mehdorn HM. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurological research. 2010; 32(8):816-820.
7. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Loffler M, Weller M, Reifenberger G, Tonn JC and German Glioma N. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. International journal of cancer Journal international du cancer. 2011; 129(3):659-670.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005; 352(10):997-1003.
9. Kaina B, Christmann M, Naumann S and Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA repair. 2007; 6(8):1079-1099.
10. Cejka P, Stojic L, Mojas N, Russell AM, Heinimann K, Cannavo E, di Pietro M, Marra G and Jiricny J. Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. The EMBO journal. 2003; 22(9):2245-2254.
11. O'Brien V and Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis. 2006; 27(4):682-692.
12. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF and Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007; 26(2):186-197.
13. Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, Marra G and Jiricny J. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes&development. 2004; 18(11):1331-1344.
14. Wang JY and Edelmann W. Mismatch repair proteins as sensors of alkylation DNA damage. Cancer cell. 2006; 9(6):417-418.
15. Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-oncology. 2010; 12(3):283-288.
16. Bobola MS, Kolstoe DD, Blank A, Chamberlain MC and Silber JR. Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide. Frontiers in oncology. 2012; 2:176.
17. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England journal of medicine. 2000; 343(19):1350-1354.
18. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer research. 1990; 50(19):6119-6129.
19. Kundu CN, Balusu R, Jaiswal AS and Narayan S. Adenomatous polyposis coli-mediated hypersensitivity of mouse embryonic fibroblast cell lines to methylmethane sulfonate treatment: implication of base excision repair pathways. Carcinogenesis. 2007; 28(10):2089-2095.
20. Mohd AB, Palama B, Nelson SE, Tomer G, Nguyen M, Huo X and Buermeyer AB. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair. DNA repair. 2006; 5(3):347-361.
21. Liwak U, Jordan LE, Von-Holt SD, Singh P, Hanson JE, Lorimer IA, Roncaroli F and Holcik M. Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma Multiforme through de-repression of Bcl-xL translation. Oncotarget. 2013.
22. Asuthkar S, Velpula KK, Chetty C, Gorantla B and Rao JS. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget. 2012; 3(11):1439-1454.
23. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B and Dunn SE. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012; 3(10):1112-1123.
24. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013; 4(4):502-530.
25. Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren XQ, Belinsky MG, Lee K, Kruh GD, Kobayashi M and Akiyama S. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. International journal of cancer Journal international du cancer. 2001; 93(1):107-113.
26. Che XF, Zheng CL, Owatari S, Mutoh M, Gotanda T, Jeung HC, Furukawa T, Ikeda R, Yamamoto M, Haraguchi M, Arima N and Akiyama S. Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood. 2006; 107(12):4880-4887.
27. Ikeda R, Furukawa T, Kitazono M, Ishitsuka K, Okumura H, Tani A, Sumizawa T, Haraguchi M, Komatsu M, Uchimiya H, Ren XQ, Motoya T, Yamada K and Akiyama S. Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochemical and biophysical research communications. 2002; 291(4):806-812.